Every subtype of the IL-6-treated breast cancer cell except the S-HBCC was significantly (P-value < 0.01) more invasive and attained over a 5-fold increase compared to the control cells (SK-BR-3: 8-fold; MCF 7: 4.97-fold; and MDA-MB-231: 4.35-fold) (Figure 3B). The gene discussed is IL6; the disease is breast carcinoma.